The Oklahoma Shared Clinical and Translational Resources

The OSCTR is funded by the National Institutes of Health as part of its IDeA-CTR program. We have the mission to serve as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Clinical and Translational Science Institute

 

OCTSI is the home of the OSCTR, as well as clinical research services and dissemination and implementation resources to help improve the delivery of healthcare. 

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

2026 Oklahoma Conference for Statistics, Biostatistics and Data Science

The 2026 Oklahoma Conference for Statistics, Biostatistics and Data Science is coming soon!

Location: Hudson College of Public Health Building, Room 150 (801 NE 13th Street, Oklahoma City, OK 73104)

Conference Date: October 26-27, 2026

Contact Person(s): Chao Xu chao-xu@ouhsc.edu

Registration Deadline: October 20, 2026

Registration Cost:

2026 REDCapCon

Calling all REDCap professionals! We're excited to announce 2026 REDCapCon!

REDCapCon, an annual REDCap conference, is a three and a half-day event which offers educational and networking opportunities to REDCap administrators around the world! REDCap administrators perform a variety of functions at their institutions including technical support of the installations, end user training and support, account management, and institutional marketing of REDCap.

Subscribe to News

Recent Publications

GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus

medRxiv [Preprint]. 2026 Jul 6:2026.07.03.26357246. doi: 10.64898/2026.07.03.26357246.

ABSTRACT

BACKGROUND: Glucagon-like peptide-1 receptor agonist-based therapies (GLP) have recently emerged as promising treatments across a wide range of health conditions. These medications may have protective effects against severe long-term consequences of COVID-19 by promoting weight loss, exerting antihyperglycemic and anti-inflammatory effects, and providing cardiovascular and endothelial protection.

Media